Somnomed Limited ( (SOMNF) ) has released its Q4 earnings. Here is a breakdown of the information Somnomed Limited presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SomnoMed Limited is an Australian company specializing in the production and commercialization of oral appliances for the treatment of sleep-related disorders, particularly obstructive sleep apnea (OSA). The company operates globally, with a strong presence in Europe, North America, and Asia Pacific.
In its latest annual report for FY25, SomnoMed Limited reported a significant milestone by surpassing $100 million in annual revenue for the first time, achieving $111.5 million, which marks a 21.6% increase from the previous year. The company also returned to positive EBITDA of $9.2 million and generated free cash flow of $0.8 million, demonstrating strong operational improvements and strategic investments.
Key financial highlights include a 17% revenue growth in Europe, driven by strong performances in France, Germany, and Sweden, and a 31% increase in North America, supported by faster turnaround times and increased public awareness of sleep apnea. The Asia Pacific region also saw an 11% growth, with Australia contributing significantly to the revenue.
Looking forward, SomnoMed plans to focus on sustainable revenue and margin growth, expanding manufacturing capacity to meet increasing demand, and continuing the development of its innovative Rest Assure® technology. The company aims to further strengthen its market position and explore new opportunities in existing and emerging markets.
SomnoMed’s management remains optimistic about the future, providing guidance for FY26 with expected revenue between $119 million and $126 million and EBITDA between $10 million and $12 million. With a solid operational foundation and a commitment to innovation, the company is well-positioned to deliver long-term value to shareholders and improve patient outcomes worldwide.